Recent developments in radioimmunotherapy.
With the advent of monoclonal antibody techniques, there has been renewed interest in RIT as a treatment modality in patients with a variety of tumour types. There has been a considerable research effort to increase understanding of the scientific basis of such therapy at all levels. Antibody, chelator and radioisotope factors are all the subject of research aimed at producing a potent effector system capable of maximal target cell kill with acceptable normal tissue toxicity. Improved knowledge of the host and tumour factors which limit access to the target cell offers the possibility of optimizing targeting and increasing the therapeutic index. Target cell factors that influence response to low dose rate RIT have been elucidated and provide an opportunity to integrate the treatment modality into radical therapy regimens. A number of Phase I and II trials have now been performed in various tumour types. The results have been promising but, as yet, the prospect of radical RIT remains a research goal. Before it can be achieved it will be necessary to improve specific tumour cell targeting and to increase both the initial dose rates and the total dose delivered to tumour deposits. Until such time, it is likely that RIT will be incorporated into multimodality protocols to deliver a moderate (10-20 Gy) tumour boost, or in an adjuvant setting in patients with minimal residual disease.
Harrington
K J
KJ
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Epenetos
A A
AA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D008297:Male; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods
D000911:Antibodies, Monoclonal